Introduction to Optogenetics
"Before we can find the answers, we need the power to ask new questions." -Karl Deisseroth
In essence, optogenetics is a neural modulation technique used to control neurons in vitro for the purpose of affecting the physiology of neural circuits and ultimately behavior of the studied organism. However, in recent studies, optogenetic techniques have been used to modify nonneuronal tissues, such as cardiac tissue and beta cells, willfully controlling the respective cell-specific roles. Although the implications of optogenetics seem like a panacea for many genetic diseases, much of the field is new; in terms of therapeutics, research is regretfully far behind. Currently, optogenetic techniques are attempted mostly on rodent specimens since primate studies lack profound electrophysical and behavior effects. Optogenetic is widely associated with neuroscience research- sometimes thought as the synergy between neuroscience and synthetic biology. Current optogenetically-related research aims to ascertain brain function of multiple neural circuits, but future endeavors include gene therapy for neurodegenerative diseases and neuroprosthetics.
The basis is optogentics is quite simple. The neuron in question is spliced with a specific opsin gene carried by viral vector, usually a modified lentivirus. Subsequently, the encoded opsin attached to the cell membrane. Opsin are photosensitive G protein receptors or ion channels that are induced by a specific wavelength of visible light via fiber optic cable or optrode. In turn, the opsin undergoes a conformational change, eliciting a change in membrane potential. For neuronal cells, changes in membrane potential give rise to action potentials. The strength of the depolarizing current (incoming positive charged ions) is encoded in the frequency of the action potentials generated. Furthermore, synapses (gap junction between neurons) can conduct spatial or temporal summation. Even neuronal cells can be silenced with hyperpolarizing current (incoming negative or outgoing positive charged ions). In short, optogenetics provides neuroscientists with an “on/off” switch for targeted neurons.
"The brain is a world consisting of a number of unexplored continents and great stretches of unknown territory." - Santiago Ramón y Cajal
|1971||Bacteriorhodopsin (yellow and green)|
|1999||Francis Crick's Declaration|
|2002||ChR1 (blue), Zemelman and Miesenbock chARGed optogenetic system|
|2005||Millisecond-timescale, genetically targeted optical control of neural activity|
|2008||VChR1 (yellow and possibly green)|
The story behind optogenetics is a story of convergence of two seemingly unrelated fields: microbial microbiology and neuroscience. In 1971, Walther Stoeckenius and Dieter Oesterhelt discovered the transmembrane protein bacteriorhodopsin (BR) that is capable of moving ions in the presence of light. BR is highly expressed in haloarcheal membranes while a similar transmembrane protein proteorhodopsin (PR) is expressed in eubacteria. In 1977, Matsuno-Yagi and Mukohata described the ion pump channel halorhodopsin which displaces extracellular chloride ions in to the cell. As these discoveries were happening in the background, a growing desire to effectively control the neurons was ever –prevalent. During this period, neuroscientist adopted the idea that cognitive processes were distributed in various localizations of the cortex. This fact evident when lesions in specific areas would lead to loss of a specific process. Even fMRIs and PET solidified this point, but, even with these high-tech instruments, the processes themselves could not fully be understood. This would require an in detail analysis of the neural circuits that make up the localized cortical space. This would entail the use of electrodes in order to stimulate specific cells to generate action potentials. Electrode analysis and other biochemical methods provided much of the insight that we currently have on neuroscience, but this systematic approach is inherently flawed. Even though the electrodes are made extremely small in order to excite a particular cell, the electric charge permeates the cerebral space so that other close neurons are also stimulated. Such a problem defeats the purpose of ceteris paribus, since we are unable to determine whether the cell in question elicited the desired response in the first place. Moreover, to conduct a loss of function experiment, the neural tissue is question needs to be destroyed, or lesioned, but, once the tissue is destroyed, there are no methods to restored said tissue, further complicating neural circuit research. This lack of cell specificity and cellular controls encouraged neuroscientist to find alternative methods. In the 1990s, some scientist became infatuated with the idea that opsins may be the key; however, in the most part, this idea was considered too “far-fetched” to allocate resources, time, and money. In 1999 at the University of California in San Diego, Francis Crick commented that neuroscience faces the major challenge of controlling one type of cell while leaving the others unaffected. Crick even suggested that light could serve as a control tool. In 2002, Boris Zemelman, currently a UT associate professor, and Gero Miesenbock conducted the earliest genetically targeted method with rhodopsin photoreceptors in Drosophila. Also in 2002, channelrhodopsin (ChR1) was identified by Georg Nagel to contain a wider cation conductance (Na and K ions). In 2003, Channelrhodopsin-2 (ChR2) was later discovered in the same organism Chlamydomonas reinhardtii which conducts cations more than twofold greater than those of ChR1. ChR2 became the key to excitatory neuron transmission. In 2005, Karl Deisseroth, Edward S. Boyden, and Feng Zhang created a robust ChR2 optogenetic system cultured in mammalian neurons for precisely timed light driven action potentials. The term “optogenetics” was coined in 2006. In brief, the opsin genes discovered in various microbes were spliced in the neuron in order to elicit desired neural activity.
Biochemistry behind Optogenetics
The appeal of optogenetics stems from the simplicity of opsin; the opsin proteins combine the two roles of light sensitivity and ion transport while only being encoded by a single gene. Optogenetics takes advantage of opsins’ ability to activate for various wavelengths of light and ubiquitous presence of retinal in vertebrate tissue, including the brain. All types of opsin require retinal as a cofactor that serves as a magnet for photons. Interestingly, when the cofactor retinal is bound, the opsin protein is termed rhodopsin. After the retinal has diffused into the binding pocket, it is covalently attached to a lysine residue on helix 7 by the formation of protonated retinal Schiff base (RSBH+). The ionic environment of the RSBH+ determines the spectral and kinetic properties of the particular opsin. Indeed, this very characteristic has been exploited to create mutant opsin proteins in vitro through mutagenesis analysis. Also, all opsins consist of a seven-transmembrane helix oval. Furthermore, opsin proteins are typically divided into two distinct families: type I and type II. Type I consists of opsin proteins found in prokaryotes, algae, and fungi, while Type II consists of opsin proteins found in higher eukaryotic organism such as those found in the human eye. Type I begins with all-trans configuration of retinal then isomerizes to 13-cis configurations, while type II isomerizes 11-cis retinal into all-trans retinal. Unlike type II, type I opsins do not dissociate from the retinal cofactor. As previously discussed, bacteriorhodopsin (BR) was the first discovered opsin. Once light hits BR, the protein undergoes a series of protein confirmations between states that absorb light at 568 nm and 400 nm. Incidentally, the moment light strikes the opsin to the release of the hydrogen ion to the extracellular environment is known as a complete photocycle. Each photocycle is made up of multiple photointermediates with different spectral characteristics and representts a separate proton tranlocation process.
- Photon absorption initiates isomerization of bounded retinal from all-trans to 13-cis
- confirmation shift and dipole of RSHB+ raises pK, releasing RSB proton and created M intermediate (410nm maximum absorbance)
- Release RSB proton is accepted by the Asp 85
- Simultaneously, a different proton is released from an amino acid group from the proton release complex
- RSB captures proton from Asp 96 and the protein enters the N intermediate (560 nm)
- Asp 96 is repronated by cytoplasmic protons while the Schiff bases reisomerizes into all-trans retinal (630nm)
- Asp 85 transfers its proton to the PRC
In the case of halorhodopsin (HR), the photocycle does not include the depronation of RSBH+. After light induction, the proton cannot be releases because the acceptor amino acid normally found is BR has been replaced by Thr. Instead, a chloride ion is moved from through the chromophore and then sifted through the protein. Since activation of HR is meek, addition mammalian membrane trafficking signals provide robust expression of inhibition. HR is activated by yellow light. Sensory rhodopsin (SR-I) and phoborhodopsin (SR-II) are similar to BR except the opsin activates secondary messager Htr to activate an associated phosphorylation cascade. Channelrhodopsin (ChR) is also similar in homology with BR. ChR has three distinct forms: ChR1, ChR2 and VChR1. SFO mutation at Cys 128 in ChR2 leads to a twofold conductance of cations. A histine to arginine mutation in the proton donor (similar to Asp 96) leads to increased photocurrents but slows deactivation in ChR2. Chimeric proteins of ChR1 and ChR2 reduce inactivation and vary on photocurrent activity. Modifications on the proton acceptor (similar to Asp 85) in Glu 123 leads to more rapid channel closing and fast optical control of action potentials, while inactivation time is reduce- ChETA mutation. VChR1 absorbs light at a red-shifted maximum of 540nm while ChR1, ChR2, and VChR2 absorb blue light.
The Optogenetic Process
- Opsin gene is combined with a promotor to ensure the gene is active only in a specific type of cell
- Modified gene is inserted in the host brain via viral vector
- The virus infects many nerve cells but promoter only allows selected neuron to make opsin protein
- Fiber optic or optrode is inserted into brain and flashed the specific wavelength of light
- Record transformed regions
Opsin genes are transported into the target cells by transfection, viral transduction or transgenic animal lines. Although the viral delivery system isn’t cell type specific, the included promoter ensures expression only in the desired cells. In other words, the virus infects plethora of cell types, but the desired cells express the distinct promoter regions not shared by other neurons. Both lentivirus and adeno-associated virus vectors are used to transfer optogenetic circuitry into the desired cell type. Basically, the virus is loaded up with the promoter associated with the desired neuron and injected via stereotaxic needle closest to the desired region. Both lentivirus and AAV vectors induce long-term expression. However, lentivirus delivery are permanently integrated into the genome, while the AAV vectors are maintained extra-chromosomally. Even though virus delivery systems provide cell specific selection, the virus, themselves, have a limited packaging capacity. The lenitivirus can accomadate up to 10 kb while the AAV can include up to 5 kb. In response, transgenic animals can allow for bigger promoters to be used for increased specificity and increased expression.
The basis of optogenetics is to use light to elicit a physiological response within the cell. This entails the uses of technologies that can illuminate transformed regions. In brief, these technologies include, LED, one-photon laser, optical fibers, and optrodes.
After inducing the neurons with light, scientist must record the apparent behavior of the neural circuits by using electrodes, voltage sensitive fluorescent protein, and behavioral assays.
Applications of Optogenetics
Hepatology: Diabetes and Beta Cells
IGEM Take-home Message
- Mei Y and Zhang F. . pmid:22480664.
- Yizhar O, Fenno L, Zhang F, Hegemann P, and Diesseroth K. . pmid:21363959.
- Zemelman BV, Lee GA, Ng M, and Miesenböck G. . pmid:11779476.
- LaLumiere RT. . pmid:21255749.
- Doroudchi MM, Greenberg KP, Liu J, Silka KA, Boyden ES, Lockridge JA, Arman AC, Janani R, Boye SE, Boye SL, Gordon GM, Matteo BC, Sampath AP, Hauswirth WW, and Horsager A. . pmid:21505421.
- Boyden ES, Zhang F, Bamberg E, Nagel G, and Deisseroth K. . pmid:16116447.